EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study

Emmanuel Novy, Mohd H Abdul-Aziz iD, Vesa Cheng, Fay Burrows, Hergen Buscher, Amanda Corley, Arne Diehl, Eileen Gilder, Bianca J Levkovich, Shay McGuinness, Jenny Ordonez, Rachael Parke und 9 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01201-23 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Emmanuel Novy und 20 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland , Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Candidiasis, Continuous Renal Replacement Therapy, Extracorporeal Membrane Oxygenation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Prince Charles Hospital Research Foundation; ANZIC Foundation; ANZ College of Anaesthetists, SHPA; NHMRC Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicenter study describes the population pharmacokinetics (PK) of fluconazole in critically ill patients receiving concomitant extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) and includes an evaluation of different fluconazole dosing regimens for achievement of target exposure associated with maximal efficacy. Serial blood samples were obtained from critically ill patients on ECMO and CRRT receiving fluconazole. Total fluconazole concentrations were measured in plasma using a validated chromatographic assay. A population PK model was developed and Monte Carlo dosing simulations were performed using Pmetrics in R. The probability of target attainment (PTA) of various dosing regimens to achieve fluconazole area under the curve to minimal inhibitory concentration ratio (AUC 0-24 /MIC) >100 was estimated. Eight critically ill patients receiving concomitant ECMO and CRRT were included. A two-compartment model including total body weight as a covariate on clearance adequately described the data. The mean (±standard deviation, SD) clearance and volume of distribution were 2.87 ± 0.63 L/h and 15.90 ± 13.29 L, respectively. Dosing simulations showed that current guidelines (initial loading dose of 12 mg/kg then 6 mg/kg q24h) achieved >90% of PTA for a MIC up to 1 mg/L. None of the tested dosing regimens achieved 90% of PTA for MIC above 2 mg/L. Current fluconazole dosing regimen guidelines achieved >90% PTA only for Candida species with MIC

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CandidiasisContinuous Renal Replacement TherapyExtracorporeal Membrane OxygenationHumansAnti-Bacterial AgentsBody WeightCritical IllnessFluconazoleRenal Replacement Therapy

Stichwörter der Autor:innen

continuous renal replacement therapycritically ill patientsextracorporeal membrane oxygenationfluconazolepharmacokinetics

Substanzen

Anti-Bacterial AgentsFluconazole

Autor:innen und Institutionen

  • Faculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland , Brisbane, Queensland, Australia.
  • Université de Lorraine, SIMPA , Nancy, France.
  • Departement of anesthesiology, Critical care and peri-operative medicine, University hospital of Nancy , Nancy, France.
  • Department of Pharmacy, St. Vincent's Hospital , Sydney, New South Wales, Australia.
  • Department of Intensive Care Medicine, St. Vincent's Hospital , Sydney, New South Wales, Australia.
  • University of New South Wales, St Vincent's Centre for Applied Medical Research , Sydney, New South Wales, Australia.

ORCID-Profile: Mohd H Abdul-Aziz, Suzanne Parker, Jason A Roberts

Förderung

  • The Prince Charles Hospital Research Foundation; ANZIC Foundation; ANZ College of Anaesthetists
  • SHPA; NHMRC Australia

Zitieren

APA

Novy, E., Abdul-Aziz, M. H., Cheng, V., Burrows, F., Buscher, H., Corley, A., Diehl, A., Gilder, E., Levkovich, B. J., McGuinness, S., Ordonez, J., Parke, R., Parker, S., Pellegrino, V., Reynolds, C., Rudham, S., Wallis, S. C., Welch, S. A., Fraser, J. F., …, & Roberts, J. A. (2024). Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01201-23

Vancouver

Novy E, Abdul-Aziz MH, Cheng V, Burrows F, Buscher H, Corley A, et al. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01201-23

BibTeX
@article{Novy2024,
  author = {Novy, Emmanuel and Abdul-Aziz, Mohd H and Cheng, Vesa and Burrows, Fay and Buscher, Hergen and Corley, Amanda and Diehl, Arne and Gilder, Eileen and Levkovich, Bianca J and McGuinness, Shay and Ordonez, Jenny and Parke, Rachael and Parker, Suzanne and Pellegrino, Vincent and Reynolds, Claire and Rudham, Sam and Wallis, Steven C and Welch, Susan A and Fraser, John F and Shekar, Kiran and Roberts, Jason A},
  title = {Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01201-23}
}
Kostenlos starten →